Generic drugs are bioequivalent to branded medications in terms of their strength, dosage, quality, form, intended use, side effects, route of administration and pharmacological effect. They are gaining popularity in the United States as they are relatively cost-effective and do not require extensive investment in research, testing and advertising. Apart from this, the Government is promoting the adopting of generic drugs to minimize the expenditure on the healthcare system. Further, the rising prevalence of chronic ailments, such as cancer, diabetes, and cardiovascular, Alzheimer’s and Parkinson’s diseases, is also boosting the sales of generic drugs in the US. According to the US generic drug market report by IMARC Group, the market reached a value of US$ 103.8 Billion in 2018, registering a CAGR of 12.1% during 2011-2018. Looking forward, the US generic drug market size is projected to reach US$ 190.4 Billion by 2024, at a CAGR of around 10.6% during 2019-2024.
Download your US Generic Drug Market Report Sample for FREE!: https://www.imarcgroup.com/us-generics-market/requestsample
In this article, we will look at the leading manufacturers of generic drugs in the United States.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The generic products of the company cover most of the therapeutic area. It operates its business in two segments: generic medicines wherein generic pharmaceutical products in several dosage forms including tablets, capsules, injectables, inhalants, liquids, ointments and creams are manufactured and sold; and specialty medicines that deliver solutions to patients and providers via medicines, devices and services. The company’s Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Moreover, its main respiratory medications include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Besides this, its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its women's health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.
Mylan N.V., formerly known as Mylan Inc., is a pharmaceutical firm that licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The company primarily operates in two segments including generics and specialty. The generic pharmaceutical business is conducted mainly in the United States and Canada (North America); Europe, the Middle East, and Africa (EMEA); and India, Australia, Japan and New Zealand (Asia Pacific). Additionally, its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). Besides this, the company’s API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its generics segment. The firm focuses on drugs that are difficult to formulate and manufacture and typically have longer product life cycles than traditional generic pharmaceuticals.
Actavis, Inc., formerly known as Purepac Pharmaceutical Co., Inc., was established in 2005 and is based in Parsippany, New Jersey. It is currently a part of Teva Pharmaceuticals. It manufactures and commercializes generics, biologics, medical devices and branded pharmaceutical products for patients across the globe. It also provides products in urology, eye care, cardiovascular, women’s health, medical aesthetics, gastroenterology, central nervous system, and anti-infective therapeutic categories.
Sandoz International GmbH is based in Holzkirchen, Germany with development centers and manufacturing sites around the world. It operates as a subsidiary of Novartis AG and produces as well as markets generic pharmaceutical products. Additionally, it offers biosimilar, oncology injectable, respiratory, anti-infective and biotechnological products and medicines for various therapeutic areas. The organization also provides drugs to suppress recurrence of ischemic cerebrovascular disorder, lower cholesterol, and avert organ transplant rejection (kidney, liver, heart, lung, pancreas, and small intestine).
Sun Pharmaceutical Industries Limited is an Indian generic and pharmaceutical company. Its business segments include US Business including Western Europe, Canada, Australia, New Zealand and Other Markets; Indian Branded Generics Business, including Global Consumer Healthcare Business, and Emerging Markets, which include Active Pharmaceutical Ingredients (APIs). Moreover, the company's manufacturing operations are focused on producing generics, branded generics, specialty products, over-the-counter products, anti-retroviral and active pharmaceutical ingredients (APIs). Apart from this, the firm offers products for various therapy areas such as dermatology, psychiatry, neurology, cardiology, nephrology, gastroenterology, orthopedics and ophthalmology.
Par Pharmaceutical Companies, Inc. licenses, produces, markets as well as distributes generic drugs in the US. It operates through two segments including Par Pharmaceutical and Par Specialty Pharmaceuticals. Amongst these, the Par Pharmaceutical segment markets generic products under Par Pharmaceutical brand name and sterile products under the Par Sterile brand. On the other hand, the Par Specialty Pharmaceuticals segment focuses on the marketing and distribution of Nascobal Nasal Spray, a prescription vitamin B12 treatment that assists in the maintenance of remission in certain pernicious anemia patients; and Megace ES for treating anorexia, cachexia, or an unexplained significant weight loss in patients with diagnosis of AIDS.
Endo Pharmaceuticals, based in Malvern (Pennsylvania), was founded in 1920 and currently operates as a subsidiary of Endo International plc. The company researches, develops, and sells pharmaceutical products. It also offers products for therapeutic areas that include pain management in the areas of postherpetic neuralgia, osteoarthritis, migraine, and chronic pain; urology and oncology for non-muscle invasive bladder and prostate cancer; and endocrinology for central precocious puberty and hypogonadism.
Lupin Pharmaceuticals, Inc., based in Baltimore (Maryland), was founded in 2003. The company has plants in India and Thailand and it operates as a subsidiary of Lupin Limited. It develops as well as manufactures branded and generic pharmaceutical products for healthcare professionals and patients in India and the United States. It also offers generic pharmaceutical products in the areas of oral and injectable cephalosporins, cardiovascular, controlled release ANDA's, and paragraph IV's. Besides this, it also offers fermentation products; Suprax, an anti-infective product available in tablets and suspension formulations in pediatric and other physician practices for children; cephalosporin API’s; and ACE-inhibitors and cholesterol reducing agents.
Dr. Reddy’s Laboratories Limited functions as an integrated pharmaceutical company around the world. It operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI), and proprietary products. The company has a strategic partnership with GlaxoSmithKline plc to develop and market products outside India; collaboration, license and option agreement with Curis, Inc. to discover, design, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreement with Merck Serono to develop a portfolio of biosimilar compounds in oncology, primarily focusing on monoclonal antibodies.
Hospira, Inc. offers injectable drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company primarily operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation.
Browse Related Reports:
US Generic Injectables Market Report an Forecast 2019
Generic Drugs Market Report 2020-2025
Depression Drugs Market Report 2020-2025
Canada Generic Drug Market Report an Forecast 2019